BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases

JAMA Dermatology

Volumn 151, Issue 4, 2015, Pages 410-416

  Eriksson, Hanna ^a   Zebary, Abdlsattar ^a   Vassilaki, Ismini ^a   Omholt, Katarina ^a   Ghaderi, Mehran ^a   Hansson, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VALINE; VE1 ANTIBODY; BRAF PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA DETERMINATION; EMBEDDING; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SWEDEN; TISSUE FIXATION; UNIVERSITY HOSPITAL; GENE EXPRESSION REGULATION; GENETICS; MELANOMA; MIDDLE AGED; MUTATION; PATHOLOGY; PROCEDURES; SKIN TUMOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84928255138     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.3689     Document Type: Article

References (35)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
2. Rubinstein JC, Sznol M, Pavlick AC, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med. 2010;8:67.
3. Liu W, Kelly JW, Trivett M, et al. Distinct clinical and pathological features are associated with the BRAFT1799A (V600E) mutation in primary melanoma. J Invest Dermatol. 2007;127(4):900-905.
4. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239-1246.
5. Zebary A, Omholt K, Vassilaki I, et al. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. J Dermatol Sci. 2013;72(3):284-289.
6. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
7. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-365.
8. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma [published online September 29, 2014]. N Engl J Med. doi:10.1056/NEJMoa1408868.
9. Long GV, Stroyakovskiy D, Levchenko E, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma [published online September 29, 2014]. N Engl J Med. doi:10.1056/NEJMoa1406037.
10. Wilson MA, Nathanson KL. Molecular testing in melanoma. Cancer J. 2012;18(2):117-123.
11. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122(1):11-19.
12. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013;37(1):61-65.
13. Skorokhod A, Capper D, von Deimling A, Enk A, Helmbold P. Detection of BRAF V600E mutations in skinmetastases of malignant melanoma by monoclonal antibody VE1. J AmAcad Dermatol. 2012;67(3):488-491.
14. Feller JK, Yang S, Mahalingam M. Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma. Mod Pathol. 2013;26(3):414-420.
15. Wilmott JS, Menzies AM, Haydu LE, et al. BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma. Br J Cancer. 2013;108(4):924-931.
16. Colomba E, Hélias-Rodzewicz Z, Von Deimling A, et al. Detection of BRAF p. V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn. 2013;15(1):94-100.
17. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1, 120 tumor tissue samples of patients with brainmetastases. Acta Neuropathol. 2012;123(2):223-233.
18. Lade-Keller J, Kristensen LS, Riber-Hansen R, et al. A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma? J Clin Pathol. 2013;66(8):723-725.
19. Busam KJ, Hedvat C, Pulitzer M, von Deimling A, Jungbluth AA. Immunohistochemical analysis of BRAFV600E expression of primary and metastatic melanoma and comparisonwith mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol. 2013;37(3):413-420.
20. Boursault L, Haddad V, Vergier B, et al. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS One. 2013;8(8):e70826.
21. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003;9(17):6483-6488.
22. Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res. 2002;8(11):3468-3474.
23. Ihle MA, Fassunke J, König K, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p. V600E and non-p. V600E BRAF mutations. BMC Cancer. 2014;14(1):13.
24. Marin C, Beauchet A, Capper D, et al. Detection of BRAF p. V600E mutations in melanoma by immunohistochemistry has a good interobserver reproducibility. Arch Pathol Lab Med. 2014;138(1):71-75.
25. Eshani L, Cohen C, Fisher KE, Siddiqui MT. BRAF mutations in metastatic malignant melanoma: comparison of molecular analysis and immunohistochemical expression. Appl Immunohistochem Mol Morphol. 2014. doi:10.1097/PAI.0000000000000013.
26. Spittle C, Ward MR, Nathanson KL, et al. Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn. 2007;9(4):464-471.
27. Lade-Keller J, Rømer KM, Guldberg P, et al. Evaluation of BRAF mutation testingmethodologies in formalin-fixed, paraffin-embedded cutaneous melanomas. J Mol Diagn. 2013;15(1):70-80.
28. Edlundh-Rose E, Egyházi S, Omholt K, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res. 2006;16(6):471-478.
29. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19-20.
30. Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol. 2012;30(3):316-321.
31. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30(19):2375-2383.
32. Lin J, Goto Y, Murata H, et al. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer. 2011;104(3):464-468.
33. Yancovitz M, Litterman A, Yoon J, et al. Intraand inter-tumor heterogeneity of BRAFV600E mutations in primary and metastatic melanoma. PLoS One. 2012;7(1):e29336.
34. Greene VR, Johnson MM, Grimm EA, Ellerhorst JA. Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J Invest Dermatol. 2009;129(6):1483-1488.
35. Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30(20):2522-2529.